Altair
Skip to content

Trading Analysis Report: LLY

Analysis date: 2026-10-14 · Model: claude-opus-5-5 · AI-generated, not financial advice.

  • Analysis date: 2026-10-14
  • Rating: Underweight
  • Generated: 2026-10-14 17:32:22
  • TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
  • Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
  • Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

V. Portfolio Manager Decision

Rating: Underweight

Executive Summary: Underweight LLY: cut a standard-weight holding to about 60% of a standard allocation before the Oct 28-29 FOMC and a possible Oct 29 Q3 print. This is a trim to reduce risk ahead of two events, not an exit and not a bearish call on Lilly. Start tomorrow with marketable limits near the bid: two-thirds of the cut in the first two sessions and the rest by Oct 20-21, with the Oct 27 close as the hard backstop. If the earnings date cannot be confirmed, the earliest plausible event date is the deadline. Go below 60% only if tonight's 10-Q and guidance review supports it, with a floor of 45%. Make no pre-event buys, keep the 1114.08 and 1075.89 price exits, and rebuild about 10-12 points of standard weight starting roughly one week after the later event, if guidance is clean and no price line has been hit.

Current Price: 1208.74

Price Target: 1185.0

Confidence: Medium

Time Horizon: 4-8 weeks

4. Risks I'm watching

  • Q3 earnings: The date is unconfirmed (one social post says Oct 29, which would coincide with the FOMC). J&J fell after a beat and raise, so the bar is high.
  • The Q2 below-the-line costs and the liability jump need explaining in the filings.
  • Gap risk: LLY has gapped 10.3%, 9.8%, 7.1% and 4.9% in 2026, on 6–8M shares. These moves dwarf the 34-point ATR, so size positions with that in mind.